A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)
A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)
The reason for this study is to see if the study drug baricitinib is safe and effective in the treatment of JIA in participants ages 1 to 17. This study is for participants that have been enrolled in studies I4V-MC-JAHV (NCT03773978) or I4V-MC-JAHU.
Inclusion Criteria:
Exclusion Criteria:
LillyTrials@Lilly.com1-317-615-4559
clinical_inquiry_hub@lilly.com
Rosario, S2000, Argentina
543414248045
SAN M. de Tucuman, T4000AXL, Argentina
+54-381-4200180
Chongqing, 400065, China
Nîmes, 30029, France
Hamburg, 22081, Germany
Milan, 20122, Italy
Palermo, 90127, Italy
Saitama-shi, 330 8777, Japan
81120023812
Shinjuku-ku, 162-8666, Japan
81120023812
Krakow, 31-503, Poland
Moscow, 115522, Russia
Istanbul, 34098, Turkey (Türkiye)
London, WC1N 3JH, United Kingdom
61264564348
3216343801
5511 55792581
551126618840
420532234482
420727812317
+45 61333138
+33144494828
9727774513
39 091 0916666250
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
526144373003
+52 1 618 812 5351
525552561496
8183338623
+48 126198630
+48426177700
(34)936009733
+34961244792